Comparative Pharmacology
Head-to-head clinical analysis: HISTAFED versus PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HISTAFED versus PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE.
HISTAFED vs PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
HISTAFED is a combination of pseudoephedrine, a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the nasal mucosa causing vasoconstriction, and triprolidine, a first-generation antihistamine that competes with histamine for H1-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract, thereby preventing histamine-mediated effects.
Promethazine is a phenothiazine derivative that antagonizes histamine H1 receptors, reducing allergic symptoms; it also has anticholinergic, antiemetic, and sedative effects. Codeine is an opioid agonist at mu-opioid receptors, producing analgesia and antitussive effects by central mechanisms.
60 mg orally every 4 to 6 hours as needed; maximum 360 mg per day.
Adults: 5 mL (containing promethazine 6.25 mg and codeine 10 mg) orally every 4-6 hours as needed; maximum 30 mL per day.
None Documented
None Documented
3-4 hours for pseudoephedrine component; shorter in children (2-3 h), prolonged in renal impairment
Promethazine: 10-19 hours (range 5-30h); Codeine: 2.5-4 hours (rapidly metabolized); Clinical context: sustained antitussive effect from codeine despite short half-life. Half-life of promethazine extends with hepatic impairment.
Renal (approximately 65% as unchanged drug and metabolites), biliary/fecal (35%)
Renal: Codeine and metabolites ~90% (free and conjugated), Promethazine and metabolites primarily renal; minor biliary/fecal (<5% for codeine, ~6% for promethazine).
Category C
Category A/B
Antihistamine/Decongestant Combination
Antihistamine / Antiemetic